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Abstract 
Alcoholism is a complex disorder that, in man, appears to be genetically influenced, although the 
underlying genes and molecular pathways are not completely known. Here the intragastric 
alcohol feeding model in rodents was used together with high mass accuracy LC/MSn analysis to 
assess the metabonomic changes in non-polar metabolite profiles for livers from control and 
alcohol treated rats and mice. Ion signals with a peak area variance of less than 30% (based on 
repeat analysis of a pooled quality control sample analysed throughout the batch) were submitted 
to multivariate statistical analysis (using principal components analysis, PCA). PCA revealed 
robust differences between profiles from control and alcohol-treated animals from both species.  
The major metabolites seen to differ between control and alcohol-treated animals were identified 
using high accuracy MSn data and verified using external search engines 
(http://www.lipidmaps.org; http://www.hmdb.ca; http://www.genome.jp/kegg/) and authentic 
standards. The main metabolite classes to show major changes in the alcoholic liver-derived 
samples were fatty acyls, fatty acid ethyl esters, glycerolipids and phosphatidylethanol 
homologues. Significant metabolites that were up-regulated by alcohol treatment in both rat and 
mouse livers included fatty acyls metabolites such as octadecatrienoic acid and eicosapentaenoic 
acid, a number of fatty acid ethyl esters such as ethyl arachidonate, ethyl docosahexaenoic acid, 
ethyl linoleate and ethyl oleate and phosphatidylethanol (PEth) homologues (predominantly PEth 
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18:0/18:2 and PEth 16:0/18:2; PEth homologues are currently considered as potential biomarkers 
for harmful and prolonged alcohol consumption in man). A number of glycerophospholipids 
resulted in both up-regulation (m/z 903.7436 [M+H]+ corresponding to a triglyceride) and down-
regulation (m/z 667.5296 [M+H]+ corresponding to a diglyceride). Metabolite profiles were 
broadly similar in both mouse and rat models. However, there were a number of significant 
differences in the alcohol-treated group particularly in the marked down-regulation of retinol and 
free cholesterol in the mouse compared to the rat. Unique markers for alcohol treatment included 
ethyl docosahexaenoic acid.  
Metabolites were identified with high confidence using predominantly negative ion MSn data for 
the fatty acyl components to match to www.lipidmaps.org MS and MS/MS databases; 
interpreting positive ion data needed to take into account possible adduct ions which may 
confound the identification of other lipid classes. The observed changes in lipid profiles were 
consistent with alcohol induced liver injury in humans.      
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Introduction 
The challenge for global metabolite profiling is to provide novel hypothesis free, but hypothesis 
generating, insights into the phenotypes of biological systems and the chemical pathways related 
to disease and toxicity1-3.  A range of analytical tools are now available to bioscientists wishing 
to generate these metabolic phenotypes (metabotypes4) especially those using nuclear magnetic 
resonance (NMR) spectroscopy and mass spectrometry (MS)-based methods (with the latter 
most usually hyphenated to a separation system such as gas or liquid chromatography (GC or 
LC) 5-7).  
An important area where metabolic profiling might be expected to inform the understanding of 
the disease process is alcohol-related liver damage. Alcoholic liver damage has been studied 
extensively in recent years using the model of intragastric alcohol-fed mice8-11. This model has a 
number of advantages in that alcohol can be co-administered with food in a liquid form through a 
cannula inserted into the stomach and the exposure of the test animal to ethanol can, in this way, 
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be carefully controlled.  Recently there have been a number of metabolomic investigations of the 
effects of alcohol administration to rodents that have used this model based on either 1H NMR 
spectroscopy12  or a combination of NMR spectroscopy and direct infusion Fourier transform 
mass spectrometry (FT-MS)13 for metabolite profiling.  In addition a study based on LC-MS 
analysis has investigated changes in urine composition on the alcohol-induced changes seen in 
alcohol-fed male Ppara-null mice14. Here we describe the results of LC-MS-based metabonomic 
investigations on the liver metabolomes of rats and mice for the non-polar endogenous 
metabolites using intragastric alcohol-fed models, with metabolite identification via high 
accuracy MSn analysis. 
 
Methods  
Solvents and Reagents. 
All solvents used for LC/MS analysis (Chromasolv grade) were purchased from Sigma-Aldrich 
(Dorset, UK). Adrenic acid, cholesterol, 3-deoxyvitamin D3, ethyl arachidonate, ethyl oleate, 
formic acid, retinol and retinol palmitate were also purchased from Sigma-Aldrich. For the 
extraction chloroform (99%+) for spectroscopy were purchased from Acros Organics (Geel, 
Belgium) 
Animals and dosing 
Male C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and male 
Wistar rats were purchased from Harlan (Indianapolis, IN, USA).  In this study 12 male 
C57BL/6 mice and 6 male Wistar rats were separated into 3 groups (n=6 for each group). Each 
group of 6 animals was further divided into a treatment group (n=3) and a control group (n=3). 
The intragastric ethanol infusion of mice and rats was described previously8-11. 
Briefly, at the initial ethanol dose, total caloric intake derived from diet and ethanol for both 
mice and rats was initially set at 568 cal/kg/day, and the caloric percentages of ethanol, dietary 
carbohydrate (dextrose), protein (lactalbumin hydrolysate), and fat (corn oil) were 24.3%, 
15.7%, 25%, and 35%, respectively. The daily ethanol dose was increased gradually from week 
1 to week 4.  The highest caloric percentage of ethanol at the end of 4 weeks accounted for 
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34.4% of total calories.   Adequate vitamin and salt mix were included at the amounts 
recommended by the Committee on Animal Nutrition of the National Research Council (AIN-
76A, 4.42 g/L, and 15.4 g/L, respectively, Dyets Inc, PA). The animals were treated in 
accordance with the Guide for Care and Use of Laboratory Animals (NIH, Bethesda, MD, 
Publication 86-23, 1985).  
Samples and sample processing 
Liver samples were collected from control and alcohol-fed mice and rats and were frozen 
immediately on collection and stored on dry ice (solid carbon dioxide). The samples were then 
shipped on dry ice, being stored frozen at -80oC on receipt  until extraction for analysis, at which 
point they were allowed warm sufficiently to enable an  small amount (ca. 50 mg) to be removed 
and weighed. The sample for analysis was then immediately refrozen with dry ice until solvent 
extraction was performed, which was performed as soon as possible after aliquoting (within 20 
min). For extraction the frozen samples were placed in Eppendorf tubes, homogenized and 
extracted with 1mL of H2O/ACN, 50:50 (V/V), for 10 min in an ultrasonic bath (Ultrawave, 
Cardiff, UK). 
The presence of ACN in the extraction medium serves to both aid in the solubilization and 
recovery of medium to non-polar metabolites and to precipitate proteins (thereby also 
inactivating hydrolytic enzymes). The samples were then centrifuged for 10 min at 20,800g  
(Centrifuge 5417C, Eppendorf AG, Hamburg, Germany). The pellets obtained via this process 
were re-suspended in 1.5 mL of CHCl3/MeOH, 3:1 (V/V) and were then extracted for 10 min in 
the ultrasonic bath in order to obtain a the non-polar metabolite fraction for profiling.  After 
centrifugation 1.3 mL of the clear supernatant was transferred to glass vials and left over night at 
room temperature in a fume cupboard to allow the solvents to evaporate. These samples were 
then re-dissolved in 1.3 mL of MeOH and also stored at -20°C until LC/MS analysis. Quality 
control (QC) samples for these organic extracts were prepared by pooling aliquots of 40 µL of 
each sample. 
Liver Total Cholesterol 
As reported in detail elsewhere 11, liver total cholesterol was determined using the Infinity 
Cholestero Reagent Kit (Sigma Diagnostics, St Louis, MO, USA). 
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Sample analysis by LC-MS 
Both rat and mouse-derived liver extracts were analyzed, in a randomized order by LC/MS using 
a quadrupole ion trap-time of flight mass spectrometer (LCMS-IT-TOF, Shimadzu Corporation) 
using data dependent acquisitions in electrospray ionization (ESI) in both positive and negative 
mode. To identify biologically significant components, high mass accuracy MS and MSn 
fragment ion information was used to identify the most likely candidate formula.  
Prior to analysis, ten pooled QC samples were run to “condition” and provide assurance that the 
system was suitable for use.  During the analytical run itself one of these pooled QC samples was 
interspersed between every five biological samples.  
For analysis 1.0 μL of each sample (maintained at 4oC in the autosampler) were injected for 
separation by HPLC, using gradient elution, with a Prominence LC system (Shimadzu 
Corporation, Kyoto, Japan) on an Acquity BEH C18 column (2.1 x 50mm; particle size 1.7 μm) 
at a flow rate of 0.4 mL min-1, with the column maintained at 60oC. The chromatographic system 
used a binary solvent system delivered as a gradient of Solvent A (formic acid solution 0.1%) 
and Solvent B (methanol + 0.1% formic acid).  The initial gradient conditions were 95% A: 5% 
B for 0.75 min followed by a step curvi-linear gradient up to 95% B over the next 15 min.  The 
solvent composition was then held at 100% B for 6.5 min after which the column was returned to 
5% B over the next 2.5 min, making a total cycle time of 25 min per sample.  
Mass spectrometry  
All MS and MSn mass spectra were acquired on a quadrupole ion trap-time of flight mass 
spectrometer (LCMS-IT-TOF, Shimadzu, Kyoto, Japan) equipped with an electrospray source. 
This instrument is based upon the ability of a quadrupole ion trap to deliver MSn capability and 
the time of flight mass analyzer to support accurate mass measurements. The mass range is m/z 
50-5000 in MS mode and m/z 50-3000 for MSn experiments.  
The following method parameters were used for sample analysis; mass range of m/z 150-1000 in 
MS and between m/z 50-1000 in MSn mode; ion source temperature of 250°C; heated capillary 
temperature of 230°C; electrospray voltage of 4.5 kV; electrospray nebulisation gas flow was 1.5 
L/minute; detector voltage 1.75 kV; ion accumulation time was 10 msec. Automated data 
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dependent functions were set to acquire 5 scans for each precursor detected using the most 
intense ion signal as the trigger. Positive and negative ion mode were also used with a polarity 
switching time of 100 msecs. 
Mass calibration was carried out using a trifluoroacetic acid sodium solution (2.5 mmol L-1) from 
50 to 1000 Da. Data acquisition and processing used software LCMS Solution 3.50.  
Data Analysis 
Profiling Solution software (Shimadzu Corporation, Kyoto, Japan) was used to create an aligned 
data array of retention time, m/z and intensity data for both positive and negative ion data. 
Profiling Solution has been developed using a unique algorithm to generate a spectral alignment 
data matrix followed by chromatographic integration and filtering. The algorithm performed 
dynamic binning of 'likely' high resolution accurate mass spectral ions for both positive and 
negative ion data streams which were combined and reduced into a retention time-aligned 
spectrum ion intensity matrix (ion intensity in this context refers to the peak height of the ion in 
the mass spectrum) before final reduction into a profiling chromatographic matrix of ion areas. 
Data processing takes into account spectral processing parameters (mass window and retention 
time tolerance, ion intensity threshold and a parameter to adjust the isomer valley threshold) and 
chromatogram processing parameters (including QC filtering which considers a minimum 
number of pooled ions required for an ion to be included in the matrix together with limits for 
ion signal intensity and retention time variability (%RSD), sample group related parameters 
which can be applied to limit the Pval threshold).  
In this study, sample data was acquired using polarity switching mode. Profiling Solution 
software generated an aligned data array of both positive and negative ion MS data which was 
subsequently exported to SIMCA-P (Umetrics, MKS Instruments Inc., Sweden) for PCA 
analysis. Following noise reduction thresholding, a data array was processed using SIMCA-P 
and scaled to unit variance (the base weight is computed as 1/sdj, with sdj is the standard 
deviation of variable j computed around the mean). No variable was excluded in this analysis. 
Metabolite features were statistically tested for their quantitative significance by considering the 
reproducibility of the ion signal in the pooled QC sample. In order to find the major ions 
contributing to group differences these data were analyzed by OPLS-DA. Two groups were 
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defined (alcohol treated and control) and were put in two classes. The OPLS-DA S-plot 
combined the traditional loading plot and column plot confidence limits highlighting the ions of 
most significance. The x-axis provides a measure of the contribution of an ion whilst the y-axis 
provides a measure of correlation on an ion to the model. Ions furthest from the x-axis and y-axis 
are both the highest contributors to differences between groups and also have the highest 
confidence in correlation to the model. Once a metabolite feature was identified the next stage 
was to confirm the metabolite identity using empirical formula prediction software and external 
data bases.    
Formula prediction software  
To verify component identification, the Formula Predictor software was used (Shimadzu 
Corporation, Kyoto, Japan). Predicting a candidate list based on MS and MSn data takes into 
account a number of variables, including isotopic profile analysis, mass accuracy and mass 
resolution of the experimentally derived pseudo-molecular peak and related fragment ion data.  
Metabolite Identification 
Ions of significant interest were searched against external databases including; The Human 
Metabolome Database [www.hmdb.ca/], PubChem [http://pubchem.ncbi.nlm.nih.gov/], 
Biospider [http://biospider.ca/], LipidMaps [http://www.lipidmaps.com/], KEGG 
[http://www.genome.jp/kegg]. Database candidates were confirmed using Formula Prediction 
software (Shimadzu, Kyoto, Japan) to analyse isotopic profiles of MS data. 
Positive and negative ion MS/MS data allowed a greater number of metabolites to be identified 
with a higher degree of confidence. In the case of fatty acyl metabolites the reference library in 
LipidMaps was acquired using only negative ion data whereas positive ion data was used to 
identify other metabolites by comparison with databases such as HMDB, MetLin and KEGG. 
Despite the limited MS/MS information in many databases and the differing instrument 
platforms (triple quadrupoles, Q-TOF, ion trap technologies) the MS/MS information was 
critical to a high confidence metabolite identification. In the case of phosphatidylethanol 
homologues and certain fatty acid ethyl esters metabolite identification was confirmed by 
reference to published literature.  
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Metabolite Confirmation 
In order to confirm, or refute, the putative identities obtained via data base searches and mass 
spectrometric investigations a number of compounds were obtained as authentic standards for 
ions of significant interest.  This enabled their chromatographic and mass spectrometric 
characteristics to be matched against the provisional identities derived from the sample-derived 
data.  
Results  
Pooled QC sample analysis was used to assess the performance of the system by repeatedly 
injecting the QC sample throughout the analytical run every 5 samples (see refs. 15-17).   PCA 
analysis of the data set resulting from the profiling of the liver samples showed the QC samples 
to be tightly clustered together, with no obvious run order effects, for both positive and negative 
ESI data. An example of the PCA result is shown in Figure 1 for the combined positive and 
negative ion data array.  The data from the QC samples were then interrogated to determine the 
number of ions present in the samples, their intensity and their % RSD values. The aligned data 
array for both positive and negative ion MS data was filtered using the pooled QC samples; ion 
signals with high variability in ion signal intensity and/or variance in peak retention time were 
not used in the data analysis. In line with the recommendations of the FDA for biomarker 
analysis18-19 ions showing % RSDs less than 30 were used in the subsequent analysis of the test 
and control animal sample data.  Thus, the pooled QC filters were applied so that an ion should 
be present in at least 70% of the QC samples and have a variability of lower than 30% RSD 
(peak area) and 2% RSD (retention time). Profiling Solution software produced a data array of 
4963 ions that met the above criteria for a combined array for positive and negative ion data 
(1069 ions detected in negative ion; 3894 ions detected in positive ion; some 6239 ions were 
discarded as they did not meet the QC criteria). The QC data for the ions that met the required 
acceptance criteria are provided in supplementary Table S1 for positive and negative ESI results. 
Control and Alcohol-treated Rat and Mouse Liver Metabolomes 
As can be seen from the PCA analysis for the combined data array of positive and negative ion 
data shown in Figure 1, LC-MS of these extracts clearly enabled differentiation between the 
control groups for each species and between treatments. In the case of the mouse two separate 
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investigations were performed with 3 mice/group. However, the data for both investigations 
showed consistent clustering between control and treated animals, indicating a similar metabolic 
response and thereby demonstrating the repeatability of the intragastric alcohol infusion dosing 
model in the mouse.  
Major ions, highlighted by statistical methods such as OPLS-DA (Figure 2), that contributed to 
these phenotypic differences between the liver metabolomes of the two species corresponded to 
the distribution of fatty acyl metabolites (identification confirmed using the negative ion MS and 
MS/MS data corresponding to metabolites in the LipidMaps data base), fatty acid ethyl esters 
(identification of positive ion MS and MS/MS data in agreement with published data), 
glycerolipids (in agreement with positive ion mass accuracy data using KEGG, Human 
Metabolome Data Base and LipidMaps) and phosphatidylethanol (PEth) homologues 
(metabolites were identified by agreement with published MS/MS data using authentic 
standards) (Figure 3 and Figure 4). 
With respect to the effects of ethanol treatment on the liver metabolomes unique marker ions for 
the intragastric alcohol-fed model were identified by positive ion detection at m/z 333.2788, 
357.2788, 309.2788 and 311.2945 [M+H]+ corresponding to fatty acid ethyl esters, ethyl 
arachidonate, ethyl DHA (docosahexaenoic acid), ethyl linoleate and ethyl oleate. Authentic 
standards were used to identify ethyl arachidonate and ethyl oleate.  
Metabolites that were significantly down-regulated by alcohol treatment in both rat and mouse 
livers (particularly in mice) included the ion signal at m/z 369.3516 eluting with a retention time 
of 10.74 min (Figure 3).  Using only the molecular ion as part of the automated search criteria 
against several data bases (KEGG, LipidMaps, Metlin) resulted in the mis-identification of this 
metabolite as the most likely identity was given as 3-deoxyvitamin D3 ([(5Z,7E)-9,10-seco-
5,7,10(19)-cholestatriene, LMST03020618; ; MetLin MID 42544; PubChem: 49703700, 
molecular formula C27H44).  However, comparison of this ion with the retention time of the 
authentic 3-deoxyvitamin D3 standard, which was observed to elute at 14.93 min., showed that it 
differed markedly from the ion signal in the liver samples. Further investigation demonstrated 
that the unknown metabolite matched both retention time and MS/MS spectra for cholesterol 
((3β)-cholest-5-en-3-ol; m/z 369.3516 [M-H2O+H]+). Thus, the mass spectrum for the authentic 
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cholesterol standard was consistent with a positive ion base peak corresponding to a loss of water 
and a MS/MS spectra dominated by the loss of a hydrocarbon structure.  
Free cholesterol levels, as determined by a specific LC/MS based approach, were down-
regulated in all alcohol treated mouse samples and in one rat sample. This is an interesting 
observation as the liver total cholesterol assessed with cholesterol esterase methods resulted in 
~2 fold increase in the liver of alcohol infused mice and ~1.5 increase in the liver of alcohol 
infused rats11. In each of the samples with down-regulated free cholesterol amounts there was a 
corresponding increase in the amounts of cholesterol metabolites such as 7α-hydroxycholesterol 
(LipidMaps ID LMST01010013; cholest-5-en-3β,7α-diol; m/z 385.3465 [M+H -H2O]+) and 7-
keto-cholesterol (LipidMaps ID; LMST01010049; 7-oxo-cholest-5-en-3β-ol; m/z 401.3414 
[M+H]+. This overall increase in cholesterol-related material is in broad agreement with total 
cholesterol amounts measured using cholesterol esterase based methods. Clearly these effects on 
cholesterol metabolism would benefit from further, in depth, investigation of underlying 
molecular mechanisms. 
Other metabolites that were down-regulated included retinol, a diacylglycerol isomer and 
cholesteryl eicosapentaenoic acid. (Figure 5) 
Whilst the lipid profiles were broadly similar in both mouse and rat models there were a number 
of significant differences particularly in the up- and down-regulation of specific fatty acyl 
metabolites in the mouse. It was also interesting to note that retinol and cholesterol were both 
markedly down-regulated in the mouse following alcohol treatment compared to the rat. (Table 
1). 
Clinical biomarkers for alcohol exposure in man that have been considered include a number of 
minor conjugated ethanol metabolites such as ethyl glucuronide20, ethyl sulphate 21, fatty acid 
ethyl esters22 and homologues of phosphatidylethanol (PEth)23. PEth is an ethanol-derived 
phospholipid formed from phosphatidylcholine (PC) in cell membranes by a 
transphosphatidylation reaction catalyzed by phospholipase D. Previous studies have reported 
that the two predominant PEth species to monitor clinically would be 16:0/18:1 and 16:0/18:2, as 
these together accounted for approximately 60% of the total amount in blood from heavy 
drinkers. In the intragastic ethanol feeding model, the dominant PEth homologues detected in the 
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alcohol treated liver samples were PEth 18:0/18:2 and PEth 16:0/18:2 for both rat and mouse 
(Table 1). PEth 18:0/18:2 and PEth 16:0/18:2 were identified by negative ion MS accurate mass 
and MS/MS spectrum. PEth 18:0/18:2 was confirmed by accurate mass m/z 727.5283 [M-H]- and 
fragment ion data m/z 283.2643 (18:0) [C18H36O2] and 279.2330 (18:2 ) [C18H32O2]. 
Similarly, PEth 16:0/18:2 was identified by high mass accuracy MS data, m/z 699.4970 [M-H]-  
and fragment ion data corresponding to m/z 255.2330 (16:0) [C16H32O2] and m/z 279.2330 
(18:2 ) [C18H32O2]. In most control liver samples, PEth homologues were not detected. 
Discussion 
 In an earlier study that used 1H NMR spectroscopy to study ethanol-induced metabolic changes 
in liver, brain and serum from rats exposed to either a single dose or a chronic 4 day “binge” 
protocol of ethanol administration, decreased amounts of glucose, lactate, and alanine were 
measured in both liver and serum compared to control12.  The decreases in the concentrations of 
some metabolites were combined with increased quantities of acetate in both liver and serum and 
an associated increase in acetoacetate only in serum. The 4-day chronic administration also 
increased β-hydroxybutyrate in liver whilst decreasing betaine concentrations.  In a subsequent 
study urine and liver extracts from male C57BL/6J mice were analysed by 1H NMR resonance 
spectroscopy and positive ion electrospray infusion/FTICR-MS to determine the biochemical 
changes resulting from chronic alcohol administration for up to 36 days13.  In this study mice 
were fed an isocaloric control- or alcohol containing liquid diet (initially 7 g/kg/day rising to a 
final dose of 21 g/kg/day). Steatohepatitis was observed in the alcohol-fed group evidence by a 
5-fold rise in serum alanine aminotransferase activity and a 6-fold increase in liver necrosis, 
inflammation and steatosis. Increased lipid peroxidation in the livers of the ethanol-dosed 
animals was also seen as well as (amongst others)  increased acetate, alanine, lactate and 
carnitine by 1H NMR spectroscopy and 7,10,13,16-docosatetraenoic acid,  3α,20β-preganediol 
and 11,14-eicosadienoic acid by FTICR-MS. In the organic extract the ESI-FTICR analysis 
detected some 300 metabolites reproducibly.  
 
In the present study the use of LC-MS with both positive and negative ESI modes resulted in the 
repeatable detection of some 4963 ions some of which showed clear changes in response to 
alcohol administration. Here both positive and negative ESI were employed with success for the 
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detection and identification of metabolites. Thus we found that fatty acyl identities could be 
clearly distinguished using the Lipid Maps data base using negative ion mode (in the case of the 
fatty acyl metabolites, LipidMaps has MS/MS spectra in negative ion mode only). Polarity 
switching during the run was a critical discriminator enabling high confidence identification in 
negative ion mode (anion attachment in negative ion ESI-MS is less likely than cation 
attachment in positive ion ESI-MS and enables automated software routines to identify 
metabolites using deprotonated molecular information)  whilst providing information on other 
major ions in positive ion mode, such as cholesterol, which was significantly lower in mouse 
liver extracts, and somewhat reduced in the rat. The challenge, as was indeed the case for 
cholesterol, was in providing high confidence metabolite identification simply by reference to 
external data bases. In this study, mass accuracy alone did not provide a unique high confidence 
assignment especially where there are numbers of isobaric of isomers for particular atomic 
compositions. It is also important to note that positive ion MS/MS data for fatty acyl-metabolites 
are not yet included in the Lipid Maps data base. However, as is clear from the data presented in 
Table 1 there were numerous changes in non-polar metabolite profiles as a result of alcohol 
administration. Some of these changes appear to provide unique markers of alcohol 
administration in one species or another.  
 
Thus, in the case of the rat the presence of metabolites corresponding to the fatty acid ethyl 
esters, ethyl arachidonate, ethyl DHA (docosahexaenoic acid), ethyl linoleate and ethyl oleate 
would provide a unique signature of alcohol exposure, being absent in the controls. These same 
metabolites, whilst (with the exception of ethyl DHA) present in small amounts in the extracts 
obtained from mouse livers were also greatly enhanced in concentration following alcohol 
administration showing more than 10 fold increases (see Table 1). Other up-regulated 
metabolites included eicosapentaenoic acid (5 and 6 fold change in mouse and rat respectively), 
gamma-linolenic acid (GLA) (3 fold change in the rat), modocosahexaenoic acid triglyceride (3 
and 6 fold change in mouse and rat respectively) and a possible isomer of diacylglycerol (16 and 
7 fold) (Table 1). Whilst in most cases the changes in relative metabolite concentrations were the 
same for both species there were differences in the response to alcohol administration. The most 
striking change was observed for retinol palmitate and retinol in alcohol treated mice. In these 
samples, retinol palmitate and retinol were not detected in any alcohol treated sample (both 
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metabolites form m/z 269.2264 as a positive ion, the retention time and MS/MS spectra matched 
the authentic standard). Free cholesterol was also markedly lower in alcohol treated mouse (10 
fold reduction in cholesterol levels compared to the control group; the identification was verified 
using the authentic standard). This change was also noted in the rat to a lesser extent. Fatty acyl 
metabolites such as docosapentaenoic acid (DPA, clupanodonic acid), arachidonic acid (AA) and 
adrenic acid were up-regulated in the rat but down-regulated in the mouse (Table 1). 
In this study the change in metabolite profiles between animals and treatment groups has been 
measured as relative changes in ion signal intensity (peak area) to identify potential biomarkers. 
As part of further studies the development of fully quantitative assays for selected biomarkers 
will be required in order to better assess their value in understanding these models of alcohol-
induced liver injury in rodents. Proposed clinical biomarkers for ethanol consumption in man 
include the conjugated minor ethanol metabolites ethyl glucuronide and ethyl sulphate, fatty acid 
ethyl esters and fatty acid ethyl esters and PEth.  PEth is not a single molecular species but a 
group of phospholipids with a common nonpolar phosphoethanol head group onto which 2 fatty 
acid moieties, typically with a chain length of 16, 18, or 20 carbons are attached at positions sn-1 
and sn-2. In the alcohol treated liver samples of both rat and mouse, PEth 18:0/18:2 and PEth 
16:0/18:2 metabolites were detected and identified by high mass accuracy negative ion MS and 
MS/MS data. This result is in broad agreement with blood sample data taken from alcoholic 
patients24.  
Conclusions  
In this study, mass spectrometry-based metabolite profiling was used to identify changes in 
endogenous metabolite levels in intragastric alcohol-fed mice and rats models using high 
accuracy MSn analysis. Endogenous metabolites were measured and identified using a 
combination of  high accuracy polarity switching MS/MS data, acquired on a LCMS-IT-TOF 
system,  and verified by reference authentic standards and to internal and external databases 
((http://www.lipidmaps.org; http://www.hmdb.ca; http://www.genome.jp/kegg/).  
The study clearly showed a marked difference between the liver lipid profiles of alcohol treated 
mouse and rat samples with controls. The lipid profiles of mouse and rat liver samples undergo 
complex changes in lipid synthesis particularly with fatty acid ethyl esters, fatty acyls, 
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glycerolipids and phosphatidylethanol homologues. Changes in liver lipid profiles in the 
intragastic ethanol model were consistent with clinical biomarkers used in monitoring alcohol-
dependent patients during treatment.  
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Figure captions. 
Figure 1. Multivariate statistics were performed on the aligned dataset of positive and negative 
ions using Umetrics SIMCA-P+ software. The treated groups and controls were clearly separated 
in this PCA data analysis.  
Figure 2. The ‘s-plot’ is generated in the SIMCA-P+ software to help generate a list of ions that 
significantly differ between the control group and alcohol treated group. Ions of interest are 
identified using molecular formula prediction tools, comparison with MS/MS spectra and by 
querying existing data bases. (The ‘s-plot’ is presented for mouse liver samples, however, it is in 
broad agreement with rat liver metabolite profiles).  
Figure 3. Mass chromatograms for cholesterol (upper chromatogram; m/z 369.3516 (M-
H2O+H+) in positive ion mode) and linoleic acid (lower chromatogram; m/z 279.2330 (M-H)- in 
negative ion mode) in the mouse for both the control and treated group. Cholesterol was down 
regulated in the alcohol treated mouse together with retinol palmitate and retinol whilst fatty 
acids such as linoleic acid and fatty acid ethyl esters were markedly up regulated.  
Figure 4. Mass chromatograms for ethyl oleate (upper chromatogram; m/z 311.2945 (M+H)+ in 
positive ion mode) and eicosapentaenoic acid (lower chromatogram; m/z 301.2173 (M-H)- in 
negative ion mode) in the rat for both the control and treated group. The metabolite profile in the 
rat was broadly similar to the mouse. Changes in rat liver fatty acyl metabolites such as 
eicosapentaenoic acid were in close agreement to the mouse. However, there were some 
interesting differences; ethyl oleate was not present in the rat control group but was detected in 
the mouse control group.   
Figure 5. The main metabolite classes to show major changes in the alcoholic liver-derived 
samples were fatty acyls, fatty acid ethyl esters, glycerolipids and phosphatidylethanol 
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homologues. Significant metabolites that were up-regulated by alcohol treatment in both rat and 
mouse livers included fatty acyls metabolites such as octadecatrienoic acid and eicosapentaenoic 
acid, a number of fatty acid ethyl esters such as ethyl arachidonate, ethyl docosahexaenoic acid, 
ethyl linoleate and ethyl oleate and phosphatidylethanol (PEth) homologues (predominantly PEth 
18:0/18:2 and PEth 16:0/18:2; PEth homologues are currently considered as potential biomarkers 
for harmful and prolonged alcohol consumption in man). (The figure presents data for the mouse 
only, however, metabolite profiles were broadly similar in both mouse and rat models). 
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Table 1. Significant changes in metabolite levels between the control group and alcohol treated 
mouse and rat. Metabolite identification was confirmed using authentic standards in the case of 
adrenic acid, cholesterol, ethyl arachidonate, ethyl oleate, retinol and retinol palmitate or by 
agreement with external MS and MS/MS data bases using both positive and negative ESI. The 
reproducibility of ion signal intensity was measured using a pooled QC sample injected 
throughout the run (n=6, interspersed between five biological samples; QC RSD variation was 
less than 10% for all metabolites measured in the samples).  Ethyl DHA, ethyl octadecanoate, 
PEth-16:0/18:2 and PEth 18:0/18:2 were unique markers for liver samples treated with alcohol 
(these metabolites were not detected in the control group). The fold differences are measured as 
the difference between the average peak area for each treatment group compared to the control 
group for each animal. The average mass error for all reported metabolites was -0.71ppm (typical 
mass accuracy was less than 5ppm).  
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Table 1 
      Fold  
Differences 
  
Accurate 
mass  
(m/z) 
Rt 
(mins) 
Ion Formula Identification QC 
%RSD 
Mouse Rat Data base reference Supplementary information 
301.2173 6.55 [M-H]- C20H30O2 Eicosapentaenoic acid 5.8 5 6 LMFA01030759 MS2; 203; 229; 257 
277.2173 6.61 [M-H]- C18H30O2 Gamma-linolenic acid  7.5 1 3 LMFA01030141  
269.2264 6.77 [M-H2O+H]+ C20H30O Retinol  5.3 -34 -4 LMPR01090001  
327.2330 7.02 [M-H]- C22H32O2 Docosahexaenoic acid  2.5 0 2 LMFA01030185 MS2; 229; 283; 299 
303.2330 7.05 [M-H]- C20H32O2 Arachidonic acid 1.5 -1 1 LMFA01030001 MS2; 205; 231; 259; 285 
279.2330 7.10 [M-H]- C18H32O2 Linoleic acid 4.7 1 2 LMFA01030120  
305.2486 7.46 [M-H]- C20H34O2 Eicosatrienoic acid 5.6 0 6 LMFA01030158 MS2; 287 
329.2486 7.53 [M-H]- C22H34O2 Docosapentaenoic acid  3.0 -5 2 LMFA04000044 MS2; 231; 285; 311 
331.2643 7.85 [M-H]- C22H36O2 Adrenic acid  3.0 -1 6 LMFA01030178 MS2; 233; 281; 313 
401.3414 8.26 [M+H]+ C27H44O2 7-keto-cholesterol 15.0 11 9 LMST01010049 MS2; 383; 365 
357.2788 8.30 [M+H]+ C24H36O2 Ethyl DHA 6.2 Note 1 Note 1 CAS 1020718-25-5  
333.2788 8.39 [M+H]+ C22H36O2 Ethyl arachidonate 2.0 > 11 Note 1  CAS 1808-26-0 Authentic standard 
309.2788 8.48 [M+H]+ C20H36O2 Ethyl linoleate 1.1 > 22 Note 1  CAS 544-35-4  
285.2788 8.95 [M+H]+ C18H36O2 Ethyl hexadecanoate,  9.9 > 13 Note 1  CAS 628-97-7  
385.3465 9.00 [M-H20+H]+ C27H46O2 7-hydroxy-cholesterol 18.5 13 6 LMST01010013  
311.2945 9.21 [M+H]+ C20H38O2 Ethyl oleate 2.9 > 13 Note 1 CAS 111-62-6 Authentic standard 
313.3101 10.09 [M+H]+ C20H40O2 Ethyl octadecanoate 4.8 Note 1 Note 1  CAS 111-61-5  
369.3516 10.74 [M-H2O+H]+ C27H46O Cholesterol  1.5 -10 -1 LMST03020618 Authentic standard 
617.5140 12.96 [M+H]+ C39H68O5 Possible isomer Diacylglycerol 1.2 16 7 HMDB07675 Several possible isomers 
786.6007 13.27 [M+H]+ C44H84NO8P Phosphatidylcholine 5.7 2 1 HMDB08135  
667.5296 14.64 [M+H]+ C43H70O5 Possible isomer Diacylglycerol 4.0 -4 -2  HMDB07769 Several possible isomers 
269.2264 16.01 [M-C16H32O+H]+ C36H60O  Retinol palmitate  4.8 Note 2 -3 LMPR01090052 Authentic standard 
699.4970 16.79 [M-H]- C39H73O8P PEth-16:0/18:2 8.3 > 9 Note 1  Reference 24; MS2 ions 
727.5283 19.02 [M-H]- C41H77O8P PEth-18:0/18:2 8.1 > 35 Note 1  Reference 24; MS2 ions 
901.7280 19.09 [M+H]+ C59H96O6 Monoeicosapentaenoic acid 
triglyceride 
1.6 9 20 HMDB10527 Several possible isomers 
903.7436 19.60 [M+H]+ C59H98O6 Monoarachidonic acid triglyceride 2.2 5 8 HMDB10523 Several possible isomers 
671.5762 19.67 [M+H]+ C47H74O2 Cholesteryl eicosapentaenoic acid 1.4 -6 -2 HMDB06731 Several possible isomers 
905.7593 20.15 [M+H]+ C59H100O6 Monoarachidonic acid triglyceride 2.1 3 6 HMDB10521 Several possible isomers 
          
Legend Note 1; no ion signal detected in the control group samples. 
Note 2; no ion signal detected in the intra-gastric alcohol samples 
LM; LipidMaps reference 
HMDB; Human Metabolome Data Base 
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